Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Publication/Presentation Date
2-21-2021
Abstract
Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.
Volume
146
Issue
4
First Page
1157
Last Page
1162
ISSN
1364-5528
Published In/Presented At
Murray, G. F., , Guest, D., , Mikheykin, A., , Toor, A., , & Reed, J., (2021). Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population. The Analyst, 146(4), 1157–1162. https://doi.org/10.1039/d0an01769h
Disciplines
Medicine and Health Sciences
PubMedID
33426547
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article